Evidence map›Paper›PMID 15618111›Full record

GuidelineDiabetes care2005

Diagnosis and classification of diabetes mellitus.

American Diabetes Association

2 registry-linked trialsAbstract readGuidelinePractice Guideline
PubMed Publisher
In one paragraph

Guideline in Diabetes care, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 252 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05359432 phase4completedstarted 2020, after this paper: background citation

Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes Mellitus

Ran2020Enrolled120Registered outcomes10Posted comparisons0ConditionsType 2 DiabetesArmsempagliflozin, vildagliptin
PMID 16584801PMID 33835284PMID 31518657PMID 18801858other papers from this trial
Open the trial in the graph
NCT03141398 withdrawnnot on this mapstarted 2017, after this paper: background citation

Continuous Glucose Monitoring (CGM) Versus Oral Glucose Tolerance Test (OGTT) Versus T2* MRI Of The Pancreas In High-Risk Group (Hemoglobinopathies, Lymphoma & Acute Lymphoblastic Leukemia): A Comparative Study

TypeobservationalSponsorHamad Medical CorporationRan2017 to 2018Enrolled0ConditionsIron Overload, Hemoglobinopathies, Lymphoma, Acute Lymphoblastic LeukemiaArmsContinuous Glucose Monitoring (CGM), Oral Glucose Tolerance Test (OGTT), T2* MRI of the Pancreas
3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.The New England journal of medicine · 2016 · on this map
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

American Diabetes Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2HumansHyperglycemiaInsulin Resistance

Identifiers

PMID15618111

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.